Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOTHDEL is an oral gastrointestinal contrast medium used to enhance visualization during magnetic resonance imaging (MRI) procedures. The active ingredient is manganese chloride tetrahydrate, an inorganic small molecule. Upon oral administration, the manganese ions (Mn2+) act as a paramagnetic agent, shortening the longitudinal relaxation time (T1) of water protons in the gastrointestinal tract. This results in increased signal intensity on T1-weighted images, allowing for better delineation of the stomach and duodenum. It was co-developed and launched in Japan by Meiji Dairies Corporation (now Meiji) and Kyowa Hakko Kogyo (now Kyowa Kirin).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BOTHDEL.